Tag: “Huntington’s Disease Treatment Market

Categories
Uncategorized

Huntington’s Disease Treatment Is Expected To Grow At A CAGR Of 20% During 2022-2032| Fact.Mr Study

Huntington’s Disease Treatment Market Analysis by Treatment (Symptomatic Treatment of Huntington’s disease, Disease-Modifying Therapies for Huntington’s disease), by Region – Global Forecast 2022-2032

The global Huntington’s disease treatment market was estimated to have a market size worth US$ 360 Mn in 2021 and is expected to grow at a CAGR of 20% from 2022-2032. The market is estimated to reach US$ 2.7 Bn by the end of 2032.

Click here to get a sample report (with full table of contents, tables and figures):-

https://www.factmr.com/connectus/sample?flag=S&rep_id=7121

Prominent Key players of the Huntington’s Disease Treatment market survey report:

  • H. Lundbeck A/S
  • Bausch Health Companies Inc.
  • Hetero Drugs
  • Lupin Limited
  • Hikma Pharmaceuticals Plc.
  • Dr. Roddy’s Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.

Key Segments Covered in the Huntington’s disease Treatment Industry Survey

  • By Treatment

    • Symptomatic Treatment of Huntington’s disease
    • Disease-Modifying Therapies for Huntington’s disease

Need more information on our reporting methodology? Click here:-

https://www.factmr.com/connectus/sample?flag=RM&rep_id=7121

The insights for each vendor consists of:

  • Company profile
  • SWOT analysis
  • Main market information
  • Market share
  • Revenue, pricing and gross margin

What insights does the Huntington’s Disease Treatment Market report provide to the readers?

  • Huntington’s Disease Treatment fragmentation on the basis of product type, end use, and region.
  • Comprehensive assessment of upstream starting materials, downstream demand, and present market landscape.
  • Collaborations, R&D projects, acquisitions, and product launches of each Huntington’s Disease Treatment player.
  • Various regulations imposed by the governments on the consumption of Huntington’s Disease Treatment in detail.
  • Impact of modern technologies, such as big data & analytics, artificial intelligence, and social media platforms on the global Huntington’s Disease Treatment.

Full Access of this Report Is Available at

https://www.factmr.com/checkout/7121

The report covers following Huntington’s Disease Treatment Market insights and assessment that are helpful for all participants involved in the Huntington’s Disease Treatment market:

  • Data on recently introduced regulations and their impact on key industries and on demand in Huntington’s Disease Treatment
  • Latest industry Analysis on Huntington’s Disease Treatment Market, with key analysis of market drivers, trends, and influencing factors
  • Key trends Analysis of Huntington’s Disease Treatment Market and changing consumer preferences in major industries.
  • Changing Huntington’s Disease Treatment demand and consumption of diverse products
  • Major trends underlining funding by key investors in numerous countries
  • New investment opportunities in diverse technology and product or service types
  • Comprehensive data and Competitive analysis of Huntington’s Disease Treatment major players
  • Huntington’s Disease Treatment Market sales in US will grow at a steady pace, driven by growing consumer confidence and economic recovery
  • Huntington’s Disease Treatment demand forecast in Europe remains stable, as many countries such as UK, France, and Germany focus on boosting growth

Questionnaire answered in the Huntington’s Disease Treatment Market report include:

  • How the market for Huntington’s Disease Treatment has grown?
  • What is the present and future outlook of the global Huntington’s Disease Treatment on the basis of region?
  • What are the challenges and opportunities for the Huntington’s Disease Treatment?
  • Why the consumption of Huntington’s Disease Treatment highest in region?
  • In which year segment is expected to overtake segment?

Read Our Latest Article on Healthcare Domain :

https://www.factmr.com/article/124/latest-trends-in-the-healthcare-industry-how-has-it-transformed-businesses

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Reach out to us with your goals, and we’ll be an able research partner.

contact:

21st floor , 136 Sejong-daero,
Seoul,100-768
South Korea
Phone: +1 (628) 251-1583
Email: sales@factmr.com

Categories
Pharmaceutical

Huntingtons Disease Treatment Market to accumulate US$ 2.7 Bn by 2032 – Latest Fact.MR Study

In 2021, the global Huntington’s disease treatment market was pegged at US$ 360 Mn and is projected to grow at a CAGR of 20% from 2022-2032. According to a recently published Fact.MR report, it is estimated that the market will reach US$ 2.7 Bn by 2032.

Due to the global COVID-19 pandemic, the market’s growth rate slowed to 7% from 2019 until mid-2020. Online pharmacies were selling off-label drugs to manage symptoms of HD during the COVID-19 pandemic, such as antipsychotics, antidepressants, and anticonvulsants. As a result of the government-imposed blackout, clinical trials were delayed during the COVID-19 pandemic.

Request a report sample to gain compressive insights at@ https://www.factmr.com/report/huntingtons-disease-treatment-market

The market is predicted to grow at a y-o-y rate of 6.5% between 2022 and 2023. As of the second quarter of 2021, most hospitals and clinics worldwide reported an increase in the frequency of clinical visits for HD diagnosis and treatment. Ingrezza’s expected expansion of its label to include chorea associated with Huntington’s disease. This is due to the high incidence of Huntington’s disease in western countries. These are anticipated to be major market drivers.

Key Takeaways from the Market Study

  • Huntington’s disease treatment market is expected to reach US$ 432 Mn by 2022
  • Asia Pacific is expected to witness rapid growth for Huntington’s disease treatment, with 45% of revenue share
  • Symptomatic Huntington’s disease treatment will be the most sought after accounting for 98% revenue
  • North America to account for 77% of the global market for the treatment of Huntington’s disease
  • Disease modifying therapies accumulated US$ 4.2 Bn by 2021, expected to flourish at a 9.1% CAGR until 2032

Rising prevalence of rare genetic disorders amongst the urban population has increased the incidence of Huntington’s disease, with key healthcare stakeholders attempting to discover novel therapeutic approaches, providing a platform for manufacturers to expand their influence in the global market, says a Fact.MR analyst.

Competitive Landscape

In order to gain a significant share of the market, key players are focusing on new product development and partnerships.

  • In September 2021, Spark Therapeutics, Inc. (a subsidiary of F Hoffmann La Roche Ltd) will form a partnership with NeuExcell Therapeutics Inc to develop gene therapy for treating HD patients. As part of the deal, NeuExcell Therapeutics will receive upfront license fees, R&D milestone payments, and product royalties of up to approximately USD 190 Mn.
  • Teva Pharmaceutical Industries Ltd’s Austedo, a drug intended to treat chorea associated with HD, has received approval from the National Medical Products Association (NMPA) in China in May 2020. With AUSTEDO’s approval in China, the company expects to expand its patient base and revenue.
  • To present phase 3 results for candidate pridopidine at the HC Walkewright 23rd Annual Global Investment Conference, the Cantor Virtual Global Healthcare Conference, and the European Huntington Disease Network, Prilenia Therapeutics BV announced its participation in September 2021. A healthcare conference is a worthwhile opportunity to expand your customer base.

To learn more about Huntington’s disease treatment market, you can get in touch with our Analyst at@ https://www.factmr.com/connectus/sample?flag=AE&rep_id=7121

More Valuable Insights

Fact.MR, in its new offering, presents an unbiased analysis of the Huntington’s disease treatment market, presenting historical market data (2015-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of treatment (symptomatic treatment and disease modifying therapies) across five major regions (North America, Latin America, Europe, Asia Pacific and Middle Eats & Africa).

Key Segments Covered in the Huntington’s disease Treatment Industry Survey
·         By Treatment
    • Symptomatic Treatment of Huntington’s disease
    • Disease-Modifying Therapies for Huntington’s disease

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office :

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583

E-Mail: sales@factmr.com

 

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),

Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers,

Dubai, United Arab Emirates

Visit Our Website: https://www.factmr.com

 

Categories
Pharmaceutical

Huntington’s Disease Treatment Market Is Expected To Reach US$ 432 Mn By 2022 End

In 2021, the global Huntington’s disease treatment market was pegged at US$ 360 Mn and is projected to grow at a CAGR of 20% from 2022-2032. According to a recently published Fact.MR report, it is estimated that the market will reach US$ 2.7 Bn by 2032.

Due to the global COVID-19 pandemic, the market’s growth rate slowed to 7% from 2019 until mid-2020. Online pharmacies were selling off-label drugs to manage symptoms of HD during the COVID-19 pandemic, such as antipsychotics, antidepressants, and anticonvulsants. As a result of the government-imposed blackout, clinical trials were delayed during the COVID-19 pandemic.

Request Sample   https://www.factmr.com/connectus/sample?flag=S&rep_id=7121

The market is predicted to grow at a y-o-y rate of 6.5% between 2022 and 2023. As of the second quarter of 2021, most hospitals and clinics worldwide reported an increase in the frequency of clinical visits for HD diagnosis and treatment. Ingrezza’s expected expansion of its label to include chorea associated with Huntington’s disease. This is due to the high incidence of Huntington’s disease in western countries. These are anticipated to be major market drivers.

Request Customization https://www.factmr.com/connectus/sample?flag=RC&rep_id=7121

Key Takeaways from the Market Study

  • Huntington’s disease treatment market is expected to reach US$ 432 Mn by 2022
  • Asia Pacific is expected to witness rapid growth for Huntington’s disease treatment, with 45% of revenue share
  • Symptomatic Huntington’s disease treatment will be the most sought after accounting for 98% revenue
  • North America to account for 77% of the global market for the treatment of Huntington’s disease
  • Disease modifying therapies accumulated US$ 4.2 Bn by 2021, expected to flourish at a 9.1% CAGR until 2032

Rising prevalence of rare genetic disorders amongst the urban population has increased the incidence of Huntington’s disease, with key healthcare stakeholders attempting to discover novel therapeutic approaches, providing a platform for manufacturers to expand their influence in the global market, says a Fact.MR analyst.

Buy Now  https://www.factmr.com/checkout/7121

Competitive Landscape

In order to gain a significant share of the market, key players are focusing on new product development and partnerships.

  • In September 2021, Spark Therapeutics, Inc. (a subsidiary of F Hoffmann La Roche Ltd) will form a partnership with NeuExcell Therapeutics Inc to develop gene therapy for treating HD patients. As part of the deal, NeuExcell Therapeutics will receive upfront license fees, R&D milestone payments, and product royalties of up to approximately USD 190 Mn.
  • Teva Pharmaceutical Industries Ltd’s Austedo, a drug intended to treat chorea associated with HD, has received approval from the National Medical Products Association (NMPA) in China in May 2020. With AUSTEDO’s approval in China, the company expects to expand its patient base and revenue.
  • To present phase 3 results for candidate pridopidine at the HC Walkewright 23rd Annual Global Investment Conference, the Cantor Virtual Global Healthcare Conference, and the European Huntington Disease Network, Prilenia Therapeutics BV announced its participation in September 2021. A healthcare conference is a worthwhile opportunity to expand your customer base.

More Valuable Insights

Fact.MR, in its new offering, presents an unbiased analysis of the Huntington’s disease treatment market, presenting historical market data (2015-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of treatment (symptomatic treatment and disease modifying therapies) across five major regions (North America, Latin America, Europe, Asia Pacific and Middle Eats & Africa).

Key Segments Covered in the Huntington’s disease Treatment Industry Survey

  • By Treatment

    • Symptomatic Treatment of Huntington’s disease
    • Disease-Modifying Therapies for Huntington’s disease

For More Insights- https://www.prnewswire.com/news-releases/demand-for-industrial-gear-solutions-with-complex-designs-driving-gear-measuring-machines-market-factmr-301266718.html

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

4-1-1 Nakano,
9F Nakano Sunplaza
Tokyo, 164-8512
Japan

Tel: +1 (888) 863-5616